Redx Pharma plc Appointment of Peter Collum as CFO (5305X)
May 05 2021 - 2:00AM
UK Regulatory
TIDMREDX
RNS Number : 5305X
Redx Pharma plc
05 May 2021
REDX PHARMA PLC
("Redx" or the Company)
Redx Pharma announces appointment of Peter Collum, as Chief
Financial Officer
Alderley Park, 5 May 2021, Redx Pharma plc (AIM: REDX), the drug
discovery and development company focused on cancer and fibrosis,
is pleased to announce that it has appointed Peter Collum as Chief
Financial Officer (CFO). Peter will commence his role at Redx
immediately and will be based in the New York area, in the United
States.
Peter joins Redx from Pharnext SA, an advanced late-stage
clinical biopharmaceutical company, where he has been Chief
Financial Officer and Chief Business Officer since July 2019. Prior
to Pharnext, Peter spent over 17 years in healthcare investment
banking, most recently as a Partner at MTS Health Partners, a
boutique healthcare investment bank in New York, where he led and
participated in numerous M&A and financing deals for public and
private life sciences companies both in the US and internationally.
Prior to this, he worked in the healthcare investment banking group
at Bank of America, with a focus on life sciences. Peter started
his career in the pharmaceutical industry at Roche in US Technical
Operations. He holds an MBA from the Booth School of Business at
the University of Chicago and a BS from Rutgers University College
of Engineering.
Lisa Anson, Chief Executive Officer of Redx commented: "We are
delighted to welcome Peter to the Redx management team. This is an
exciting stage of Redx's development and growth as we continue to
progress on lead assets in oncology and fibrosis. Peter's extensive
experience in the US and with US investors will be invaluable as we
continue to deliver on our ambition towards becoming a leading
biotech company with a robust pipeline of valuable, differentiated
targeted medicines in areas of high unmet medical need."
Peter Collum commented: "I am very pleased to be joining Redx at
such an exciting time for the Company. Over the past few years,
Redx has made significant progress, both financially and
operationally, and I look forward to working alongside its strong
leadership team to deliver the next stage of growth."
As previously announced, James Mead will transition from his
current role of Chief Financial Officer to the new role of Chief
Operations Officer at Redx, and will continue to be based in
Alderley Park, Cheshire at the Company's laboratories and head
office. Neither the COO nor the CFO will be Directors of the
Company.
In addition, the Company announces that on 4 May 2021, options
over 1,500,000 ordinary shares of 1p each in the share capital of
the Company, were granted to Peter Collum on the following
basis:
The options were granted with an exercise price of 65p per
share, being the closing price on 30 April 2021.
Name Position Number of Options Vesting Date Total Options
Granted Held Following
the Grant
Peter Collum Chief Financial
(PDMR) Officer 100,000 4 May 2022
100,000 4 May 2023
100,000 4 May 2024
4 May 2024
(subject to
performance
1,200,000 conditions) 1,500,000
Following the grant referred to above, the Company will have
granted options over a total of 33,348,764 Ordinary Shares
representing 12.2 per cent. of the share capital in issue. The
number of options that may be awarded remains limited such that the
aggregate number of Ordinary Shares of 1p each under option will be
less than 15 per cent. of the total issued share capital of the
Company.
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name Peter Collum
--------------------------------- ------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status Chief Financial Officer
--------------------------------- ------------------------------------
b) Initial notification/Amendment Initial Notification
--------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Redx Pharma Plc
--------------------------------- ------------------------------------
b) LEI 213800HMS4EBXO589Y37
--------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Options over Ordinary Shares of 1p
instrument each
--------------------------------- ------------------------------------
b) Identification code ISIN: GB00BSNB6S51
--------------------------------- ------------------------------------
c) Nature of the transactions Grant of options
--------------------------------- ------------------------------------
d) Price(s) and volume(s) Exercise price: 65 pence per share
Volume: 1,500,000 shares
--------------------------------- ------------------------------------
e) Aggregated information As for d) above
- Aggregated volume
- Price
--------------------------------- ------------------------------------
f) Date of the transactions 4 May 2021
--------------------------------- ------------------------------------
f) Place of the transactions Off-market
--------------------------------- ------------------------------------
For further information, please contact:
Redx Pharma Plc T: +44 1625 469
918
Iain Ross, Chairman
Lisa Anson, Chief Executive
SPARK Advisory Partners (Nominated Adviser) T: +44 203 368
3550
Matt Davis/Adam Dawes
WG Partners LLP (Joint Broker) T: +44 20 3705
9330
Claes Spång/Nigel Birks/David Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 20 7886
2500
Rupert Dearden/Freddy Crossley/Emma Earl
FTI Consulting T: +44 20 3727
1000
Simon Conway/Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and
development of novel targeted medicines for the treatment of cancer
and fibrotic disease, aiming to progress them to clinical proof of
concept. Redx's lead oncology asset, RXC004, is currently in a
phase 1 study in patients with advanced malignancies with top line
data expected in mid-2021 and the Company's selective ROCK2
inhibitor, RXC007, is expected to enter a phase 1 clinical study in
H1 2021.
The Company's core capability of converting medicinal chemistry
insights into differentiated and commercially attractive small
molecule drug candidates against clinically validated targets has
been recognized by others. Over the last three years the company
has completed four major preclinical stage deals with AstraZeneca,
Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAKSLEDSFEFA
(END) Dow Jones Newswires
May 05, 2021 02:00 ET (06:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Jul 2023 to Jul 2024